WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an immunogenic Aβ fragment linked to an immunoglobulin carrier molecule to form a conjugate and an adjuvant, wherein the adjuvant enhances an immune response comprising antibodies to the Aβ fragment.

2. The pharmaceutical composition of claim 1, wherein the Aβ fragment is from the N-terminal half of Aβ.

3. The pharmaceutical composition of claim 2, wherein the Aβ fragment is Aβ1-5.

4. The pharmaceutical composition of claim 3, wherein Aβ1-5 consists of the first five N-terminal amino acids of SEQ ID NO:1.

5. The pharmaceutical composition of claim 2, wherein the Aβ fragment is Aβ1-6.

6. The pharmaceutical composition of claim 5, wherein Aβ1-6 consists of the first six N-terminal amino acids of SEQ ID NO:1.

7. The pharmaceutical composition of claim 2, wherein the Aβ fragment is Aβ1-12.

8. The pharmaceutical composition of claim 7, wherein Aβ1-12 consists of the first 12 N-terminal amino acids of SEQ ID NO:1.

9. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises alum.

10. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises monophosphoryl lipid (MPL).

11. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises Quillaja Saponaria Molina (QS21).

12. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises GM-CSF.

13. The pharmaceutical composition of any one of claims 1-8, wherein the adjuvant comprises M-CSF.

14. The pharmaceutical composition of any one of claims 1-8, which comprises greater than 10 μg of the Aβ fragment.

15. The pharmaceutical composition of any one of claims 1-8, which comprises at least 20 μg of the Aβ fragment.

16. The pharmaceutical composition of any one of claims 1-8, which comprises at least 50 μg of the Aβ fragment.

17. The pharmaceutical composition of any one of claims 1-8, which comprises at least 100 μg of the Aβ fragment.

18. The pharmaceutical composition of claim 1, wherein the adjuvant is selected from the group consisting of alum, monophosphoryl lipid (MPL), Quillaja Saponaria Molina (QS21), GM-CSF, and M-CSF.

19. The pharmaceutical composition of claim 18, which comprises greater than 10 μg of the Aβ fragment.

20. The pharmaceutical composition of claim 18, which comprises at least 20 μg of the Aβ fragment.

21. The pharmaceutical composition of claim 18, which comprises at least 50 μg of the Aβ fragment.

22. The pharmaceutical composition of claim 18, which comprises at least 100 μg of the Aβ fragment.

23. The pharmaceutical composition of claim 18, wherein the Aβ fragment is from the N-terminal half of Aβ.

24. The pharmaceutical composition of claim 23, wherein the Aβ fragment is Aβ1-5.

25. The pharmaceutical composition of claim 24, wherein Aβ1-5 consists of the first five N-terminal amino acids of SEQ ID NO:1.

26. The pharmaceutical composition of claim 23, wherein the Aβ fragment is Aβ1-6.

27. The pharmaceutical composition of claim 26, wherein Aβ1-6 consists of the first six N-terminal amino acids of SEQ ID NO:1.

28. The pharmaceutical composition of claim 23, wherein the Aβ fragment is Aβ1-12.

29. The pharmaceutical composition of claim 28, wherein Aβ1-12 consists of the first 12 N-terminal amino acids of SEQ ID NO:1.